CancerDrs

Leukemia clinical trials

300 actively recruiting leukemia trials in the United States. Cancers of the blood and bone marrow. Clinical trial participation is historically higher for leukemia than most solid tumors.

Data from ClinicalTrials.gov · last refreshed · Leukemia stats on SEER

93
Phase 1
124
Phase 2
10
Phase 3
1
Phase 4
72
Other

Leukemia by the numbers (U.S.)

66,890
Estimated new cases (2025)
23,540
Estimated deaths (2025)
67.8%
5-year relative survival
68
Median age at diagnosis

Source: NCI SEER Cancer Stat Facts

Browse leukemia trials by state

Texas 104 California 81 New York 80 Ohio 69 Massachusetts 58 Florida 56 North Carolina 50 Pennsylvania 47 Georgia 44 Maryland 44 Illinois 41 Tennessee 40 Washington 40 Colorado 33 Michigan 31 New Jersey 31 Wisconsin 31 Minnesota 30 Oregon 30 Missouri 28 Arizona 24 Utah 23 Virginia 22 Alabama 20 Connecticut 19 Kansas 18 Iowa 17 Kentucky 15 South Carolina 15 Louisiana 14 Arkansas 12 District of Columbia 11 Nebraska 11 Indiana 10 Oklahoma 10 Nevada 9 Rhode Island 9 West Virginia 8 Delaware 7 Mississippi 7 New Mexico 7 Maine 6 Idaho 5 Montana 5 Hawaii 4 New Hampshire 4 North Dakota 4 South Dakota 4 Alaska 3 Vermont 2 Wyoming 2

Top trials by phase + site coverage

Phase 3 Recruiting Industry

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutatio…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06852222
Locations:
  • University of Alabama at Birmingham — Birmingham, Alabama
  • Cancer Treatment Center of America Phoenix — Goodyear, Arizona
  • The University of Arizona Cancer Center — Tucson, Arizona

+ 45 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This…

Sponsor: Kura Oncology, Inc.
NCT ID: NCT07007312
Locations:
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
  • University of California, Fresno — Clovis, California
  • University of California, San Diego — La Jolla, California

+ 31 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

This is a multi-center, randomized, double-blinded, placebo controlled trial.

Sponsor: Priothera SAS
NCT ID: NCT05429632
Locations:
  • University of Alabama Hospital (UAB Hospital) — Birmingham, Alabama
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
  • City of Hope Comprehensive Cancer Center - Duarte — Duarte, California

+ 18 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …

Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Locations:
  • Pacific Cancer Medical Center, Inc — Anaheim, California
  • TOI Clinical Research — Cerritos, California
  • Stanford School of Medicine-Cancer Clinical Trials Office — Palo Alto, California

+ 16 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS)…

Sponsor: Amgen
NCT ID: NCT04994717
Locations:
  • City of Hope National Medical Center — Duarte, California
  • University of California Irvine — Orange, California
  • University of California San Francisco — San Francisco, California

+ 4 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

This pivotal phase 2/3, multi-center, adaptive design study of L-Annamycin for Injection in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with refractory/relapsed AML is divided into…

Sponsor: Moleculin Biotech, Inc.
NCT ID: NCT06788756
Locations:
  • Bioresearch Partners — Miami, Florida
  • Augusta University - Georgia Cancer Center — Augusta, Georgia
  • University of Nebraska Medical Center — Omaha, Nebraska

+ 3 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrut…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05947851
Locations:
  • Highlands Oncology Group ( Site 5405) — Springdale, Arkansas
  • MemorialCare Health System - Long Beach Medical Center ( Site 5421) — Long Beach, California
  • Memorial Hospital West ( Site 5410) — Pembroke Pines, Florida

+ 3 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

This is a Phase 3, randomized, open-label, multicenter study comparing rocbrutinib (LP-168) versus pirtobrutinib in adult participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who h…

Sponsor: Newave Pharmaceutical Inc
NCT ID: NCT07342478
Locations:
  • Optum Medical Group (Rhodes) P.C. — Las Vegas, Nevada
  • OSU Comprehensive Cancer Center — Columbus, Ohio
  • UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Global Trial in APG2575 for Patients With CLL/SLL

This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors

Sponsor: Ascentage Pharma Group Inc.
NCT ID: NCT06104566
Locations:
  • MD Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317649
Locations:
  • Banner University Medical Center - Tucson — Tucson, Arizona
  • University of Arizona Cancer Center-North Campus — Tucson, Arizona
  • University of Arkansas for Medical Sciences — Little Rock, Arkansas

+ 216 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML)…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554406
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona
  • Banner University Medical Center - Tucson — Tucson, Arizona

+ 208 more sites in the U.S.

View on ClinicalTrials.gov →

Showing 12 of 300 trials. See all on ClinicalTrials.gov

Before you contact a trial site

Trial eligibility criteria are specific and strict. Reading them carefully before calling a site saves time. These guides walk through what to look for.

How to read clinical trial eligibility →

Inclusion, exclusion, biomarker requirements, performance status, and prior-therapy rules.

 How to find a clinical trial →

Search strategy, matching services, and when to involve your oncologist.

 Clinical trial phases explained →

Phase 1 through 4, what each means for patients.

 Insurance coverage for clinical trials →

The ACA requires coverage of routine patient costs. How to appeal denials.

Medical disclaimer: Information on this page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-11